• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1982株呼吸道病原体和1921株泌尿道病原体对19种抗菌药物的体外敏感性:一项加拿大多中心研究。加拿大抗菌研究小组

In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group.

作者信息

Blondeau J M, Yaschuk Y, Suter M, Vaughan D

机构信息

Division of Clinical Microbiology, Saskatoon District Health and St Paul's Hospital (Grey Nuns) and the University of Saskatchewan, Saskatoon, Canada.

出版信息

J Antimicrob Chemother. 1999 Mar;43 Suppl A:3-23. doi: 10.1093/jac/43.suppl_1.3.

DOI:10.1093/jac/43.suppl_1.3
PMID:10225567
Abstract

A total of 3903 pathogens from 48 Canadian medical centres were tested against 19 antimicrobial agents. Five agents showed activity against > or = 90% of all 1982 respiratory tract pathogens tested (ciprofloxacin, 90%; cefoperazone, 91%; ticarcillin/clavulanate, 92%; ceftazidime and imipenem, 93% each). Nine agents had > or = 90% activity against Enterobacteriaceae from respiratory tract infection (cefotaxime and ticarcillin/clavulanate, 90% each; aztreonam, ceftizoxime and ceftriaxone, 91% each; ceftazidime, 93%; ciprofloxacin, 97%; imipenem and netilmicin, 98% each). Similarly, five agents had activity against > or = 90% of all 1921 urinary tract pathogens tested (ciprofloxacin and ticarcillin/clavulanate, 90% each; cefoperazone and netilmicin, 91% each; imipenem, 99%). Nine agents had > or = 95% activity against Enterobacteriaceae from urinary tract infection (ciprofloxacin, 95%; cefotetan, 97%; aztreonam, cefotaxime, ceftazidime, ceftizoxime, ceftriaxone and netilmicin, 98% each; imipenem, 99%). Seventeen agents had activity against > or = 95% of Staphylococcus aureus strains. Susceptibility of Pseudomonas aeruginosa isolates ranged from 2% to 91%.

摘要

来自加拿大48个医疗中心的总共3903种病原体针对19种抗菌药物进行了测试。五种药物对所有1982种测试的呼吸道病原体中的≥90%表现出活性(环丙沙星,90%;头孢哌酮,91%;替卡西林/克拉维酸,92%;头孢他啶和亚胺培南,各93%)。九种药物对呼吸道感染的肠杆菌科细菌有≥90%的活性(头孢噻肟和替卡西林/克拉维酸,各90%;氨曲南、头孢唑肟和头孢曲松,各91%;头孢他啶,93%;环丙沙星,97%;亚胺培南和奈替米星,各98%)。同样,五种药物对所有1921种测试的泌尿道病原体中的≥90%表现出活性(环丙沙星和替卡西林/克拉维酸,各90%;头孢哌酮和奈替米星,各91%;亚胺培南,99%)。九种药物对泌尿道感染的肠杆菌科细菌有≥95%的活性(环丙沙星,95%;头孢替坦,97%;氨曲南、头孢噻肟、头孢他啶、头孢唑肟、头孢曲松和奈替米星,各98%;亚胺培南,99%)。十七种药物对≥95%的金黄色葡萄球菌菌株有活性。铜绿假单胞菌分离株的敏感性范围为2%至91%。

相似文献

1
In-vitro susceptibility of 1982 respiratory tract pathogens and 1921 urinary tract pathogens against 19 antimicrobial agents: a Canadian multicentre study. Canadian Antimicrobial Study Group.1982株呼吸道病原体和1921株泌尿道病原体对19种抗菌药物的体外敏感性:一项加拿大多中心研究。加拿大抗菌研究小组
J Antimicrob Chemother. 1999 Mar;43 Suppl A:3-23. doi: 10.1093/jac/43.suppl_1.3.
2
Canadian Pseudomonas aeruginosa susceptibility study from 48 medical centers: focus on ciprofloxacin.
Int J Antimicrob Agents. 1998 Nov;10(4):297-302. doi: 10.1016/s0924-8579(98)00049-1.
3
Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.使用Etest方法对哥伦比亚六种广谱β-内酰胺类抗生素的耐药性进行多中心评估。哥伦比亚抗菌药物耐药性研究小组。
Diagn Microbiol Infect Dis. 1997 Dec;29(4):265-72. doi: 10.1016/s0732-8893(97)00157-0.
4
In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa.哌拉西林、替卡西林、美洛西林、替卡西林-克拉维酸、氨曲南、头孢他啶、阿洛西林、头孢哌酮和硫霉素对铜绿假单胞菌的体外活性。
Clin Ther. 1986;8(6):655-7.
5
In vitro activity of 19 antimicrobial agents against 3513 nosocomial pathogens collected from 48 Canadian medical centres. The Canadian Antimicrobial Study Group.19种抗菌药物对从48家加拿大医疗中心收集的3513株医院病原体的体外活性。加拿大抗菌研究小组。
Int J Antimicrob Agents. 2000 Aug;15(3):213-9. doi: 10.1016/s0924-8579(00)00170-9.
6
Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.利用替卡西林-克拉维酸、头孢他啶及其他广谱抗菌药物的体外试验结果预测肠杆菌科细菌、铜绿假单胞菌及其他细菌对哌拉西林-他唑巴坦的敏感性
Diagn Microbiol Infect Dis. 1994 Nov;20(3):143-9. doi: 10.1016/0732-8893(94)90108-2.
7
Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: real or perceived? Fluoroquinolone Resistance Surveillance Group.美国众多医疗中心重要病原菌的流行情况及注射用药物的抗菌活性,I. 关于新出现耐药性威胁的研究:真实的还是感知到的?氟喹诺酮耐药性监测组
Diagn Microbiol Infect Dis. 1994 Aug;19(4):203-15. doi: 10.1016/0732-8893(94)90033-7.
8
Antimicrobial susceptibility of respiratory isolates of Enterobacteriaceae and Staphylococcus aureus in Italy: incidence and trends over the period 1997-1999.意大利肠杆菌科细菌和金黄色葡萄球菌呼吸道分离株的抗菌药敏性:1997 - 1999年期间的发病率及趋势
Eur J Clin Microbiol Infect Dis. 2001 Dec;20(12):854-63. doi: 10.1007/s100960100628.
9
Ro 17-2301: in vitro comparison with aztreonam, imipenem, ceftazidime, cefotaxime and netilmicin.Ro 17 - 2301:与氨曲南、亚胺培南、头孢他啶、头孢噻肟和奈替米星的体外比较
Chemotherapy. 1985;31(4):279-85. doi: 10.1159/000238348.
10
[Comparative activity of ticarcillin-clavulanic acid and various beta-lactams against Pseudomonas maltophilia].替卡西林-克拉维酸与多种β-内酰胺类药物对嗜麦芽窄食单胞菌的比较活性
Pathol Biol (Paris). 1987 Jun;35(5 Pt 2):805-8.

引用本文的文献

1
Description and validation of a spectrum score method to measure antimicrobial de-escalation in healthcare associated pneumonia from electronic medical records data.一种基于电子病历数据测量医疗相关肺炎抗菌药物降阶梯治疗的谱评分方法的描述与验证
BMC Infect Dis. 2015 Apr 25;15:197. doi: 10.1186/s12879-015-0933-9.
2
Antibiotic susceptibility patterns among respiratory isolates of Gram-negative bacilli in a Turkish university hospital.土耳其一家大学医院革兰氏阴性杆菌呼吸道分离株的抗生素敏感性模式
BMC Microbiol. 2004 Aug 22;4:32. doi: 10.1186/1471-2180-4-32.
3
Carbapenems in serious infections: a risk-benefit assessment.
碳青霉烯类药物用于严重感染:风险效益评估
Drug Saf. 2000 Mar;22(3):191-4. doi: 10.2165/00002018-200022030-00003.